Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179055 · ClinicalTrials.gov registry record · Phase 2
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
A Phase 2 study of Dry Eye, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 5
- Study locations
NCT07179055: Recruiting Phase 2 study of Dry Eye, sponsored by Vanda Pharmaceuticals.
NCT07179055 is a Phase 2 study of Dry Eye that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 160 participants, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07179055, a Phase 2 study of Dry Eye, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Primary Outcome
Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VSJ-110
Study Locations (5)
California
- Vanda Investigational Site - Newport Beach
Massachusetts
- Vanda Investigational Site - Andover
North Carolina
- Vanda Investigational Site - Shelby
Tennessee
- Vanda Investigational Site - Memphis
Virginia
- Vanda Investigational Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-10 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT07179055 shows while recruiting
NCT07179055 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07179055 lists 5 locations in 5 states (California, Massachusetts, North Carolina).
Frequently Asked Questions
What is clinical trial NCT07179055 about?
NCT07179055 is a clinical study titled "An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye". The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
What is the current status of trial NCT07179055?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-10. Estimated completion is 2026-09.
What conditions does trial NCT07179055 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT07179055?
The interventions under investigation include: Placebo (DRUG), VSJ-110 (DRUG).
Who is sponsoring clinical trial NCT07179055?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07179055 being conducted?
This trial has 5 study locations across California, Massachusetts, North Carolina, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07179055's enrollment target sits among peer trials
160 5th of 41 higher than 36 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia